Partial Seizures Associated with Antiphospholipid Antibodies in Childhood

Angelini, Lucia; Granata, Tiziana; Zibordi, Federica; Binelli, S.; Zorzi, Giovanna; Besana, Carlo

doi:10.1055/s-2007-973570

Cited by 39 publications

(31 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All types of epilepsy were seen and the seizures were generally well controlled with antiepileptic drugs. In a series of children with cryptogenic partial epilepsy 13% had high titres of antiphospholipid antibodies, all with frontal lobe seizures and normal imaging, whereas none were found in the control groups 43. One case had refractory seizures, which resolved with the temporary addition of corticosteroids.…”

Section: Antibodies Associated With Unselected Patients With Epilepsymentioning

confidence: 91%

Epilepsy: an autoimmune disease?

Palace

2000

Journal of Neurology, Neurosurgery &Amp; Psychiatry

View full text Add to dashboard Cite

Section: Antibodies Associated With Unselected Patients With Epilepsymentioning

confidence: 91%

Epilepsy: an autoimmune disease?

Palace

2000

Journal of Neurology, Neurosurgery &Amp; Psychiatry

View full text Add to dashboard Cite

“…These changes have, however, been traditionally associated with either antiepileptic drug exposure (e.g., phenytoin), autoimmune diseases, or recurrent infections [4][5][6]. More recently, serum antiphospholipid antibodies have been observed in 19%-26% of adult [7][8][9] and pediatric [10][11][12] patients with both chronic epilepsy and newly diagnosed seizure disorders. Angelini et al [12] found serum antiphospholipid antibodies in 13% of patients with partial epilepsy.…”

Section: Introductionmentioning

confidence: 99%

“…More recently, serum antiphospholipid antibodies have been observed in 19%-26% of adult [7][8][9] and pediatric [10][11][12] patients with both chronic epilepsy and newly diagnosed seizure disorders. Angelini et al [12] found serum antiphospholipid antibodies in 13% of patients with partial epilepsy. Peltola et al [13] also showed glutamic acid decarboxylase (GAD) antibodies in a number of patients with refractory localization-related epilepsy, although these data have not been confirmed by other authors [14].…”

Section: Introductionmentioning

confidence: 99%

Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients

Verrotti¹,

Greco

Altobelli

et al. 2003

Clinical and Experimental Medicine

View full text Add to dashboard Cite

To explore the hypothesis that raised anticardiolipin antibodies, glutamic acid decarboxylase, and antinuclear antibodies may be associated with epilepsy and/or pharmacoresistance, we studied titers in 74 epileptic patients and 50 controls. Epileptic patients were divided into two groups according to their response to anticonvulsant therapy. Group I included 52 children (30 females and 22 males with a mean age+/-SD of 7.0+/-2.4 years) suffering from different types of epilepsy who were treated with various anticonvulsants. Group II included 22 children (10 females and 12 males with a mean age of 6.2+/-3.6 years) suffering from therapy resistant epilepsy. We found that the prevalence of anticardiolipin antibodies was significantly higher in epileptic patients than in controls, while there was no significant difference between patients who were seizure free and those with uncontrolled epilepsy. No significant difference was found in glutamic acid decarboxylase antibodies between epileptic children and controls, and between patients who were seizure free and those with uncontrolled epilepsy. A significant difference in the incidence of antinuclear antibodies was found between epileptic children and controls, while no difference was found between well-controlled and drug-resistant epilepsy. In conclusion, the prevalence of anticardiolipin and antinuclear antibodies was higher in patients with epilepsy than in controls. There was no significant difference in serum glutamic acid decarboxylase antibodies between epileptic children and controls, and between patients who were seizure free and those with uncontrolled epilepsy.

show abstract

“…Another trial158 described in detail the brain injury seen in SLE patients with APS, finding frequent epilepsy (and stroke) with an increase of thrombotic and non-thrombotic brain injures. Angelini et al159 suggested that aPLs play a role in the immune-mediated pathogenic mechanism for partial epilepsy. Verrot et al160 reported that aCL was present in 20% of patients and was independent of the type of epilepsy, the antiepileptic treatment, or the age or sex of the patients.…”

Section: Aps and Vaso-ischemic (Occlusive) Diseases With Neuropsychiamentioning

confidence: 99%

Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview

Atanassova

2007

Yonsei Med J

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is primarily considered to be an autoimmune pathological condition that is also referred to as "Hughes syndrome". It is characterized by arterial and/or venous thrombosis and pregnancy pathologies in the presence of anticardiolipin antibodies and/or lupus anticoagulant. APS can occur either as a primary disease or secondary to a connective tissue disorder, most frequently systemic lupus erythematosus (SLE). Damage to the nervous system is one of the most prominent clinical constellations of sequelae in APS and includes (i) arterial/venous thrombotic events, (ii) psychiatric features and (iii) other non-thrombotic neurological syndromes. In this overview we compare the most important vascular ischemic (occlusive) disturbances (VIOD) with neuro-psychiatric symptomatics, together with complete, updated classifications and hypotheses for the etio-pathogenesis of APS with underlying clinical and laboratory criteria for optimal diagnosis and disease management.

show abstract

Partial Seizures Associated with Antiphospholipid Antibodies in Childhood

Cited by 39 publications

References 3 publications

Epilepsy: an autoimmune disease?

Epilepsy: an autoimmune disease?

Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients

Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview

Contact Info

Product

Resources

About